New combo attack shows promise for Oligo-Metastatic lung cancer

NCT ID NCT03965468

Ongoing Disease control Sponsor: ETOP IBCSG Partners Foundation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests a combination of immunotherapy (durvalumab), chemotherapy (carboplatin and paclitaxel), and targeted radiation to metastatic spots, followed by surgery or radiation to the main lung tumor. The goal is to see if this aggressive approach can keep the cancer from growing for at least a year in people with non-small cell lung cancer that has spread to only a few other sites. The study enrolled 96 participants and is no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (Imfinzi), Carboplatin, Paclitaxel
What this could lead to: If successful, this combination approach could improve control of advanced lung cancer that has spread to a few other sites, potentially extending life without progression.
What could go wrong: This is a mid-stage trial with only 96 participants and no comparison group, so results may not be definitive. Side effects from chemotherapy, immunotherapy, and radiation can be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER OLIGOMETASTASIS STAGE IV

Contacts and locations

Locations

Centre Hospitalier Universitaire Vaudois (CHUV)

Lausanne, Switzerland
Erasmus Medical Centre

Rotterdam, Netherlands
European Institute of Oncology

Milan, Italy
Geneva University Hospital

Geneva, Switzerland
Hosp. De la Santa Creu i Sant Pau

Barcelona, Spain
Hosp. Sanchinarro- Centro Integral Oncología Clara Campal

Madrid, Spain
Hosp. Uni. Politécnico La Fe

Valencia, Spain
Hosp. Uni. Virgen de las Nieves

Granada, Spain
IRCCS Istituto Nazionale Tumori Regina Elena

Roma, Italy
Inselspital Bern

Bern, Switzerland
Istituto Oncologico Veneto - Irccs

Padova, Italy
Kantonsspital Winterthur

Winterthur, Switzerland
Maastricht University Medical Center

Maastricht, Netherlands
University Hospital Zurich

Zurich, Switzerland
Vall d'Hebron University Hospital

Madrid, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.